Postmenopausal bleeding (PMB) is vaginal bleeding in postmenopausal women, which is different from that we expect in women who use sequential hormonal substitution therapy (1). Every postmenopausal bleeding, whether it is spot-like or heavy, requires further evaluation of these patients. It can be caused by benign changes in endometrial, which can be diffuse (hyperplasia and atrophy), focal (endometrial polyp), and malignant (2-4). Endometrial cancer represents 6% of all female cancers. In the U.S., Canada, and Western Europe endometrial cancer is diagnosed in 8% to 12 % of all malignancies of women while in Eastern Europe it is diagnosed in 2% to 4 % (5). Cancer of uterine corpus is the sixth among cancers in women in the region of Vojvodina (6). Incidence of endometrial cancer depends on age. In women aged 40 years endometrial cancer occurs in 12/100 000, and in women aged 60 years it is 84/100 000 (7). Only 4% of these patients with endometrial cancer are women younger than 40 years, and 25 % are women in premenopausal period. Approximately 75% of endometrial cancers occur in postmenopausal period, and 50 % of these are associated with risk factors (7). Numerous multicentre epidemiological studies pointed to their existence and a high correlation between endometrial cancer and risk factors. There are endogenous and exogenous risk factors. Ninety percent of patients with endometrial cancer visit a gynecologist because of vaginal bleeding in the form of menometrorrhagia in perimenopause or menstruation-like bleeding in postmenopause (8). Possibility that the postmenopausal bleeding is caused by endometrial cancer depends on patients age and it is diagnosed at approximately 9% of women 50 years old, 16% women 60 years old, 28% those of 70 years, and 60% at women of 80 years (9). Thus, it is necessary examine every PMB and find out the cause of it. Basic diagnostic approach considers (9): -Anamnesis and gynecological examination -Transvaginal ultrasound -Methods of sampling endometrial tissue for histopathological analysis -Additional diagnostic methods
INTRODUCTION
Postmenopausal bleeding (PMB) is vaginal bleeding in postmenopausal women, which is different from that we expect in women who use sequential hormonal substitution therapy (1) . Every postmenopausal bleeding, whether it is spot-like or heavy, requires further evaluation of these patients. It can be caused by benign changes in endometrial, which can be diffuse (hyperplasia and atrophy), focal (endometrial polyp), and malignant (2) (3) (4) . Endometrial cancer represents 6% of all female cancers. In the U.S., Canada, and Western Europe endometrial cancer is diagnosed in 8% to 12 % of all malignancies of women while in Eastern Europe it is diagnosed in 2% to 4 % (5). Cancer of uterine corpus is the sixth among cancers in women in the region of Vojvodina (6) . Incidence of endometrial cancer depends on age. In women aged 40 years endometrial cancer occurs in 12/100 000, and in women aged 60 years it is 84/100 000 (7) . Only 4% of these patients with endometrial cancer are women younger than 40 years, and 25 % are women in premenopausal period. Approximately 75% of endometrial cancers occur in postmenopausal period, and 50 % of these are associated with risk factors (7) . Numerous multicentre epidemiological studies pointed to their existence and a high correlation between endometrial cancer and risk factors. There are endogenous and exogenous risk factors. Ninety percent of patients with endometrial cancer visit a gynecologist because of vaginal bleeding in the form of menometrorrhagia in perimenopause or menstruation-like bleeding in postmenopause (8) . Possibility that the postmenopausal bleeding is caused by endometrial cancer depends on patients age and it is diagnosed at approximately 9% of women 50 years old, 16% women 60 years old, 28% those of 70 years, and 60% at women of 80 years (9) . Thus, it is necessary examine every PMB and find out the cause of it. Basic diagnostic approach considers (9) : -Anamnesis and gynecological examination -Transvaginal ultrasound -Methods of sampling endometrial tissue for histopathological analysis -Additional diagnostic methods
MATERIAL AND METHODS
Our retrospective study included 122 patients in postmenopausal period that came to a gynecologist because of bleeding from uterus. We used data of patients who had their last period at least one year ago. Basic clinical data were taken from the hospital records of the Oncology Institute of Vojvodina and Clinic for Gynecology and Obstetrics, Clinical Center of Vojvodina. After gynecological and examination by transvaginal ultrasound, the patients underwent fractionate explorative curettage in local or short-term intravenous anesthesia. Histopathological analysis of the samples was done in the Department for pathology and cytological diagnostics, Oncology Institute of Vojvodina, and Center for pathology and histology, Clinical Center of Vojvodina. Based on histopathological findings the patients were classified in two groups: -Group A -patients with endometrial cancer -Group B -absence of malignity, benign changes (hyperplasia of endometrium, myoma, endometrial polyp, atrophic endometrium).
Clinical and histopathological characteristics in patients with postmenopausal bleeding

Statistical processing
During statistical data processing, we calculated descriptive statisticsfrequency, percent, mean values, and standard deviation. We presented our results using column charts, pie, histograms, and box-whiskers diagrams. We used t-test and analysis of variants for comparisons, to establish whether there was statistical significant difference between mean values numerical features. Significant differences (p< 0.05) were marked with *, and highly significant differences (p< 0.01) with **.
RESULTS
The study results were obtained after the analysis and statistical processing of hospital records of 122 patients. 
Figure 1. Histopathological findings in group A
According to differentiation degree of endometrial cancer, 35.6% of patients were well differentiated (G1), 45.8% were moderately differentiated (G2), and in 18.6% it was a poor differentiated tumor ( Figure 2 ). Average age of patients with endometrial cancer was 64.49 years. The youngest patient had 50 years, and the oldest had 88 years. Average value of BMI was 30.55. Menarche averagely appeared at 13.51 year, and average regular cycle was 29.1 days. Transvaginal ultrasound examination showed that the average length of uterus corpus was 6.41 cm, and endometrial thickness was 13.36 mm (Table 3) .
Histopathological findings in the B group showed that it is endometrial hyperplasia in 52.4%, in 25.4% it was diagnosed polyp, and in 19% atrophic endometrium, while submucous myoma was diagnosed in 3.2%. Submucous myoma was confirmed after hysterectomy ( Figure 3 ). Average age of patients in the B group with benign changes was 58.81 years, the youngest was 46, and the oldest was 79 years old. Average weight was 78.73 kg, and height 162 cm. Average BMI was 29.92. Average time of menarche appearing in examined benign group was 13.6 year, and average regular cycle was 28.44 days. Transvaginal ultrasound examination measured the average length of uterus corpus was 5.25 cm, with minimal length 3 cm and maximal 10 cm. Average endometrial thickness was 11.99 mm (Table 3) . Menopause appeared averagely in 50 year of life, and average duration of postmenopausal period was 9.11 years (Table 4) . We used t-test for equality of mean for testing of statistical significance between numerical variables of examined groups. Statistical significance was confirmed for age, length of uterus, and duration of menopause in both groups. Group of patients with malignant changes of endometrium was, on average, older (64.49 compared with 58.81 years); corpus of uterus was longer (6.41 compared with 5.25 cm), and their menopause lasted longer (13.67 compared to 9.11 years) ( 
DISCUSSION
Endometrial cancer is most often diagnosed tumor of female genital tract in developed countries (9) . In developing countries as well as it is in our country there is rising tendency for incidence of this cancer (10, 11) . In 75% of cases, endometrial cancer appears in women in menopause so we can talk about cancer of older population. Incidence of endometrial cancer rises from 2/100 000 of women under 40 years old to 40-50/100 000 of women in sixth, seventh, and eight decade of life (12) . Average age of women with endometrial cancer in our study was 64.49 years and that is a statistically significant difference from women with benign changes of endometrium with average age of 58.8 years.
However, 25% of endometrial cancer appears in premenopausal period while 5% of diagnoses are established among women younger than 40 years (13) . The risk for developing endometrial cancer is associated bleeding (1). Due to decreased production of estrogen after menopause, the appearance of the endometrium is changed and it becomes atrophic and on ultrasound examination, it appears as a thin line that represents stratum basale (19) . Histological examination indicates that thickness of endometrium rarely exceeds 3 mm in physiological conditions. In addition, it is not possible to visualize endometrium in 7% to 10% of women in postmenopause that do not bleed from uterus (20) . Numerous studies tried to define the threshold for thickness of endometrium by means of transvaginal ultrasound, which could indicate the existence of pathological changes in the endometrium. Smith-Bindman et al. make the meta-analysis of 35 studies and find that the sensitivity for detection of pathological changes on an endometrium is more than 92% if the endometrial thickness is 5 mm (21) . A large multicentre study that included 1168 women with postmenopausal bleeding and the thickness of an endometrium 4 mm or less was conducted in Norway; of these women, Karlsson et al. diagnosed 14 who had pathological changes such as hyperplasia and polyp of endometrium. However, there was no cancer diagnosed. If we took this value as a threshold for appearance of pathological changes in an endometrium, the sensitivity would range from 96%, specificity 68%, PPV 61%, NPV 97%, and overall accuracy was 78%. When the threshold was 5 mm, sensitivity was 94%, specificity 78%, PPV 69%, NPV 96%, and overall accuracy was 84%.
In an endometrium with thickness less than 5 mm, risk of appearance of pathological changes was 5.5% (22) . Curcic established the threshold of endometrial thickness of 5 mm with sensitivity of 98%, specificity 44%, PPV 51%, NPV 98% for prediction of cancer and confirmed certainty for detection of endometrial cancer for this threshold (23) . In our study, average endometrial thickness of the examined women with postmenopausal bleeding was 12.66 mm. In the group with verified endometrial cancer, average endometrial thickness was 13.36 mm while it was 12 mm in the group with benign changes. Although there was obvious difference between average endometrial thicknesses, statistical significance was not confirmed. In addition, we did not determine that there was a significant difference in endometrial thickness regardless whether the change was malignant or benign. Curcic et al. confirmed significantly thicker endometrium in women with endometrial cancer concerning the women with benign changes (23) . The same author established the statistical significance for the length of uterus in longitudinal section in women with malignancy with regard to benign group. In our study, we found that the length of uterus in longitudinal section was statistically different in patients with endometrial cancer compared to those with benign changes. If we measured only the endometrial thickness in the both groups of patients, we would not be able to diagnose the real cause of PMB. The mean measurements of an endometrium are pathologic in the both groups, and all of these women were definitely indicated for histopathological analysis of the endometrium. The use of transvaginal ultrasound examination for diagnosis of pathological changes in endometrium is still the first diagnostic tool. Any thickness greater than 5 mm in the setting of postmenopausal bleeding or any endometrial heterogeneity or focal thickening seen at transvaginal US should be investigated . Therefore, there is no place to use it as a screening method in a general population. Langer et al. report that if the endometrial thickness is 5 mm or more, explorative curettage will be needed at half of those women, but only 10% of them would be diagnosed with age of women. Therefore, longer postmenopausal period increases the risk for developing malignant change in endometrium (12) . In our study, we confirmed statistically significant difference in length of postmenopausal period in women with malignant than in women with benign changes of endometrium. Numerous studies report that obesity is important risk factor for developing of endometrial cancer (14) (15) (16) (17) . In our study, we did not confirm the difference in BMI between women with malignant and benign changes, since the total mean value for BMI for both groups is 30.32 and according to the classification of level of nutrition, all of them were obese. Based on that we can confirm that every endometrial change developed at the examined women, whether they are malignant or benign, depend of given risk factor, obesity. Vermenlen, in his study, pointed to estrone as major estrogen for women in postmenopausal period, which is predominantly created by peripheral aromatization of circulating androstenedione (18) . Incubation of adipose tissue in vitro using androstenedione and 19-hydroxsiandrostenedion as substrate showed conversion mostly to estrone. How is it going that production of estrone is associated with obesity degree, therefore stimulation of endometrium should be identical in both groups. Among women in the postmenopausal period, bleeding from the genital organs is the main sign to visit a gynecologist. Malignant change and endometrial cancer also lead to postmenopausal bleeding. Although in 90% there is vaginal bleeding in endometrial cancer, cancer is cause of postmenopausal bleeding in 25% cases, so it is necessary to bear in mind other causes of bleeding from the genital organs. Gynecological examination is indispensable in order of distinguish the cause of 
Endometrial cancer is most often diagnosed tumor of female genital tract in developed countries (9) . In developing countries as well as it is in our country there is rising tendency for incidence of this cancer (10, 11) .
In 75% of cases, endometrial cancer appears in women in menopause so we can talk about cancer of older population. Incidence of endometrial cancer rises from 2/100 000 of women under 40 years old to 40-50/100 000 of women in sixth, seventh, and eight decade of life (12) .
Average age of women with endometrial cancer in our study was 64.49 years and that is a statistically significant difference from women with benign changes of endometrium with average age of 58.8 years. However, 25% of endometrial cancer appears in premenopausal period while 5% of diagnoses are established among women younger than 40 years (13) . The risk for developing endometrial cancer is associated with age of women. Therefore, longer postmenopausal period increases the risk for developing malignant change in endometrium (12) . In our study, we confirmed statistically significant difference in length of postmenopausal period in women with malignant than in women with benign changes of endometrium.
Numerous studies report that obesity is important risk factor for developing of endometrial cancer (14) (15) (16) (17) . In our study, we did not confirm the difference in BMI between women with malignant and benign changes, since the total mean value for BMI for both groups is 30.32 and according to the classification of level of nutrition, all of them were obese. Based on that we can confirm that every endometrial change developed at the examined women, whether they are malignant or benign, depend of given risk factor, obesity.
Vermenlen, in his study, pointed to estrone as major estrogen for women in postmenopausal period, which is predominantly created by peripheral aromatization of circulating androstenedione (18 (27) . The problem in differential diagnosis of the PMB cause during standard vaginal ultrasound examination is to distinguish focal from diffuse changes and benign from malignant changes. Today we use hysteroscopy and sonohysterography in distinguishing diffuse from focal changes (28) (29) (30) .
Histopathological analysis of endometrial sample is the best method for establishing the diagnosis of endometrial cancer. Explorative curettage is not anymore a golden standard for getting the sample of endometrium; today, it is less invasive endometrial biopsy. If we use special aspirate biopters (Pipelle or Vabrata) possibility for complications during explorative curettage are reduced. It is estimated that more than 50% curettages do not discover pathological changes of endometrium (31) . Explorative curettage is associated with surgical complications including perforation in 0.6%-1.3%, bleeding in 0.4%, and infections in 0.3%-0.5% cases (32) . Multiple studies show that the diagnostic curettage in diagnosis of irregular uterine bleeding is increasingly replaced by less invasive procedures such as endometrial biopsy or hysteroscopy, which are performed in outpatient conditions (30, 31, 33) . In developed countries, curettage is a method of choice only if biopsy in outpatient facilities or direct hysteroscopy cannot be done. In the nowadays studies we can see that an endometrial biopsy is method of choice for diagnosis of premalignant and malignant endometrial condition; if there is focal endometrial lesion this method is not highly sensitive, unlike the hysteroscopy or sonohysterography (30) (31) (32) (33) .
CONCLUSION
Women with longer postmenopausal interval and PMB have higher risk for detection of endometrial cancer. Endometrial thickness measured by transvaginal ultrasound is not sufficient parameter for differencing benign from malignant endometrial changes. Patients with endometrial cancer have statistically significant longer uterine corpus than patients with benign endometrial changes. Body mass index (BMI) was not a significant risk factor for endometrial cancer. In the both groups obesity is diagnosed which indicates BMI as a risk factor for developing of pathological changes in endometrium which could causes clinical symptom, PMB.
